{
  "abstract": "Background The integration of both transcriptomic and proteomic data from the same tissue section has long been a challenge in translational research and drug discovery, particularly when working with formalin-fixed paraffin-embedded (FFPE) samples. To address this need, we have developed and validated a novel multiomics workflow on the nCounter® Analysis System that enables simultaneous quantification of mRNA and protein targets from the same slide. This ‘multiomics made simple’ approach is uniquely enabled by Bruker Spatial Biology’s streamlined workflow and direct hybridization chemistry, now accessible and validated through NeoGenomics.Methods The core innovation of this application lies in its ability to measure both mRNA and protein signal from a single FFPE slide as part of a simple 3-step workflow. The assay leverages the nCounter mRNA Panels such as the PanCancer IO 360™ Panel that measures up to 800 gene expression targets alongside newly designed and optimized Protein Panels capable of analyzing up to 800 proteins within a unified protocol. To validate performance specifications, NeoGenomics, a leading clinical research organization, evaluated the multiomics application across diverse FFPE sample types, including breast, lung, colorectal, bladder, thyroid, and DLBCL cancers.Results Across all tissue types, the streamlined assay demonstrated high specificity, strong correlation between replicate runs, and excellent dynamic range for both mRNA and protein analytes. These results confirm the platform’s utility across a wide range of tumor biology contexts and support its adoption for biomarker discovery, target validation, and mechanism-of-action studies. By enabling integrated mRNA+Protein analysis on a single tissue section, the nCounter platform allows researchers to identify disease-related signatures to accelerate translational workflows with greater confidence in biological insights and reduced technical complexity.Conclusions This newly validated application, available through NeoGenomics, empowers research teams to explore the synergistic potential of multiomics using a simple, scalable, and reproducible workflow—making same-slide mRNA+Protein analysis a practical reality for pharma and translational research teams.",
  "authors": [
    {
      "affiliations": [
        "NeoGenomics Laboratories, Houston, TX, USA"
      ],
      "name": "Kirsteen Maclean"
    },
    {
      "affiliations": [
        "NeoGenomics Laboratories, Houston, TX, USA"
      ],
      "name": "Sergio Hernandez"
    },
    {
      "affiliations": [
        "NeoGenomics Laboratories, Houston, TX, USA"
      ],
      "name": "Brigitte Lovell"
    },
    {
      "affiliations": [
        "NeoGenomics Laboratories, Houston, TX, USA"
      ],
      "name": "Lisa Duncan"
    },
    {
      "affiliations": [
        "NeoGenomics Laboratories, Houston, TX, USA"
      ],
      "name": "Lakshmi Chandramohan"
    },
    {
      "affiliations": [
        "Bruker Spatial Biology, Seattle, WA, USA"
      ],
      "name": "Christina M Bailey"
    },
    {
      "affiliations": [
        "Bruker Spatial Biology, Seattle, WA, USA"
      ],
      "name": "Wei Yang"
    },
    {
      "affiliations": [
        "Bruker Spatial Biology, Seattle, WA, USA"
      ],
      "name": "Shanshan He"
    },
    {
      "affiliations": [
        "Bruker Spatial Biology, Seattle, WA, USA"
      ],
      "name": "Joe Beechem"
    }
  ],
  "title": "115 Validation of a simplified mRNA+protein multiomics workflow on the nCounter® Platform using FFPE tissue: results from a comprehensive analytical validation across multiple tumor types",
  "uid": "398190e2-3f05-550d-8efb-01bd03fb7acc"
}